Last Modified Date Product NameBrief Description
 2018-05-30 Time-to-event Bayesian Optimal Interval (TITE-BOIN) Design for Phase I Clinical Trials The time-to-event Bayesian optimal interval (TITE-BOIN) design provides a novel approach to accelerating phase I trials by allowing for real-time dose assignment for new patients while some enrolled patients’ toxicity data are still pending. It addresses the common logistic issue that the observation of toxicity cannot keep up with the patient accrual, caused by late-onset toxicity or fast accrual. The TITE-BOIN dose escalation/de-escalation rule can be tabulated before the trial begins, making it transparent and simple to implement. The TITE-BOIN yields superior performance comparable to that of the more complicated model-based time-to-event continuous reassessment method (TITE-CRM), with better overdose control.
 2018-05-24 Bayesian Optimal Interval (BOIN) Design for Phase I Clinical Trials The Bayesian optimal interval (BOIN) design is a novel phase I dose-finding trial design that optimizes patient treatment ethics by minimizing the chance of exposing patients to sub-therapeutic and overly toxic doses. The BOIN design is implemented in a simple way similar to the traditional 3+3 design, but is more flexible and possesses superior operating characteristics that are comparable to those of the more complex model-based designs, such as the continual reassessment method (CRM).
 2018-05-03 Bayesian Update for Two Beta-Binomial Distributions An interactive application to show the Bayesian update of two beta-binomial distributions.
 2018-04-06 Bayesian Optimal Phase 2 (BOP2) Design A flexible Bayesian optimal design for phase II trials with a single binary, co-primary, nested or bivariate binary endpoints.
 2018-03-15 Sample Size Calculation - Continuous Endpoint Shiny app provides a free, online, easy-to-use sample size calculator for normal data. Includes the sample size calculation for one, two or more groups.
 2018-02-02 A Phase I/II Design to Identify Optimal Biological Dose for Molecularly Targeted Agents This design is used to find the optimal biological dose (OBD) for molecularly targeted agents and immunotherapy agents, considering both toxicity and efficacy. The OBD is defined as the dose that is safe and has the highest efficacy.
 2018-01-04 Simon's Two-Stage Design The Simon's two stage design is a commonly used phase II design. It controls type 1 and type 2 errors, and is optimal in the sense that the expected (or maximum) sample size is minimized if the regimen has low activity (i.e., under the null hypothesis).
 2017-12-05 Bayesian Optimal Interval Design (BOIN) for Drug Combination Trials BOIN for Drug Combination trials is a web-based interactive application to find maximum tolerated dose (MTD) or MTD contour for phase I drug combination trial.
 2017-08-31 Bayesian Efficacy Monitoring with Posterior Probability Bayesian efficacy monitoring with options of early futility and/or efficacy stopping using posterior probability.
 2017-08-31 Bayesian Efficacy Monitoring with Predictive Probability Bayesian efficacy monitoring with options of early futility and/or efficacy stopping using predictive probability.
 2017-08-31 Bayesian Hierarchical Model - Binomial Data An interactive application for Bayesian Hierarchical Model - Binomial Data.
 2017-08-31 Bayesian Hierarchical Model - Normal Data An interactive application for Bayesian Hierarchical Model - Normal Data.
 2017-08-31 Bayesian Toxicity Monitoring Bayesian toxicity monitoring for evaluating drug safety.
 2017-08-31 Bayesian Update for a Beta-Binomial Distribution An interactive application to show the Bayesian update of a beta-binomial distribution.
 2017-08-31 Bayesian Update for a Normal Distribution with Known and Unknown Variance An interactive application to show the Bayesian update of a normal distribution.
 2017-08-31 Parameter Estimation for A Diagnostic Test An interactive application to calculate the post-test disease probability given the disease prevalence, sensitivity and specificity of a diagnostic test.
 2017-08-31 Varying Cut-Point and Parameter Estimation of the ROC Curve Analysis An interactive application to calculate the post-test disease probability given the disease prevalence, marker distributions in the disease group and no-disease group by varying the cut-off point of the marker.
 2017-06-17 Keyboard: a novel Bayesian toxicity probability interval design for phase I clinical trial The keyboard design provides an upgrade to the modified toxicity probability interval (mTPI) design, with a substantially lower risk of overdosing patients and the better precision to identify the maximum tolerated dose (MTD). The keyboard design is an intuitive Bayesian design that conducts dose escalation and de-escalation based on whether the strongest key, defined as the dosing interval that most likely contains the current dose, is below or above the target dosing interval. The keyboard design can be implemented in a simple way, similar to the traditional 3+3 design, but provides more flexibility for choosing the target toxicity rate and the better precision to identify the MTD.
 2017-05-18 Screening for New Onset Diabetes A web based application for screening for new onset diabetes for CPDPC16-01
 2016-08-15 Toxicity Severity Weight Visualizer Shiny app used to visualized the design of severity weights by physicians for different kinds of toxicities

DISCLAIMER: Unless otherwise stated on a subsequent application-specific web page, these programs are for research purposes only. We provide absolutely no warranty of any kind, either expressed or implied, including but not limited to the implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the quality and performance of these programs is with the user. Should any of these programs prove defective, the user assumes the cost of all necessary servicing, repair, or correction. In no event shall The University of Texas or any of its component institutions, including MD Anderson Cancer Center, be liable for damages, including any lost profits, lost monies, or other special, incidental or consequential damages arising out of the use of or inability to use these programs (including but not limited to loss of data or its analysis being rendered inaccurate or losses sustained by third parties).